Phase I study of FF-10501-01 in patients with Myelodysplastic Syndrome and continuous administration study
Phase of Trial: Phase I
Latest Information Update: 26 May 2017
At a glance
- Drugs FF 10501 (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Toyama Chemical
- 28 Apr 2017 Status changed from recruiting to completed.
- 24 Dec 2015 According to a Strategia Therapeutics media release, a total of 5 dose cohorts (50-400 mg/m2 orally twice daily) have been enrolled. Additional Phase 1 dose cohorts of 500, 600 and 800 mg/m2 BID will be assessed. The Phase 2 portion of the study will open when a recommended Phase 2 dose is determined
- 24 Dec 2015 Interim results published at the 57th American Society of Hematology Meeting, according to a Strategia Therapeutics media release.